SL
REGN icon

Salomon & Ludwin’s Regeneron Pharmaceuticals REGN Stock Holding History

Salomon & Ludwin’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.2K Sell
42
-16
-28% -$10.9K ﹤0.01% 949
2026
Q1 		$44.2K Buy
58
+16
+38% +$12.2K ﹤0.01% 550
2025
Q4 		$32.1K Sell
42
-3
-7% -$2.04K ﹤0.01% 583
2025
Q3 		$27K Buy
+45
New +$25.4K ﹤0.01% 640

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Salomon & Ludwin's REGN Position: Q2 2026 in Review

Salomon & Ludwin reduced its Regeneron Pharmaceuticals (REGN) stake by 28% in Q2 2026, selling an estimated $10.9K and leaving 42 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #949.

Salomon & Ludwin first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $44.2K in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Salomon & Ludwin held 42 shares of Regeneron Pharmaceuticals worth $26.2K as of Q2 2026.
  • Salomon & Ludwin sold 16 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $10.9K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #949 holding.
  • Salomon & Ludwin first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Salomon & Ludwin's Regeneron Pharmaceuticals position peaked at $44.2K in Q1 2026.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.